Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma

Alexander M. Menzies; Maria Gonzalez; Alex Guminski; Omgo E. Nieweg; Kerwin F. Shannon; John F. Thompson; Richard Kefford; Sydney Ch’ng; Jonathan R. Stretch; Andrew J. Spillane; J. Lee; H. Lee; Rony Kapoor; Louise Emmett; Helen Rizos; Robyn P.M. Saw; Richard A Scolyer; Georgina V. Long

doi:10.1093/annonc/mdx377.007

Related publications

Article2016

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

Robyn P.M. Saw, Alexander M. Menzies, Alexander Guminski, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Sydney Ch’ng, Richard Kefford, John F. Thompson, Jonathan R. Stretch, Andrew J. Spillane, Richard A Scolyer, Georgina V. Long

Article2017

A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)

Maria Gonzalez, Alexander M. Menzies, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Julie R. Howle, Omgo E. Nieweg, Kerwin F. Shannon, Sydney Ch’ng, Jonathan R. Stretch, Matteo S. Carlino, Alexander Guminski, Louise Emmett, Helen Rizos, Richard A Scolyer, Georgina V. Long

Article2019

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long, Robyn P.M. Saw, Serigne Lo, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, Jenny Lee, Hansol Lee, Peter M. Ferguson, Robert V. Rawson, James S. Wilmott, John F. Thompson, Richard Kefford, Sydney Ch’ng, Jonathan R. Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J. Spillane, Richard A Scolyer,

Article2015

Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Robyn P.M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna P. Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A Scolyer, Helen Rizos, John F. Thompson, Kerwin F. Shannon, Andrew J. Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long

Article2024

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

Georgina V. Long, Matteo S. Carlino, George Au‐Yeung, Kerwin F. Shannon, David Gyorki, Edward Hsiao, Rony Kapoor, Jake Thompson, Iris Batula, Julie R. Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P.M. Saw, Thomas E. Pennington, Serigne Lo, Richard A Scolyer, Alexander M. Menzies